Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Celldex Therapeutics (NASDAQ:CLDX) and maintained a price target of $67.
June 18, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Celldex Therapeutics (NASDAQ:CLDX) and maintained a price target of $67.
The reiteration of an Overweight rating and a maintained price target of $67 by a reputable analyst can boost investor confidence in Celldex Therapeutics, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100